



**SUPPLEMENTAL / BID BULLETIN**  
**UNIVERSITY OF THE PHILIPPINES MANILA**  
*The Health Sciences Center*  
**Bids and Awards Committee 1**  
Taft Avenue, Manila  
Trunk Line No. 8554-8400 Local 3014/3015



**BID BULLETIN NO. 2024-021**

**for the Supply and Delivery of Various Drugs and Medicines  
for Charity In-Patient and Resale – Ampules / Vials  
for CY 2024 (Framework Agreement)  
8 February 2024**

Pursuant to Section 22.5.1 of the 2016 Revised Implementing Rules and Regulations of Republic Act No. 9184, the Bids and Awards Committee 1 is issuing this bid bulletin to modify or amend the following items in the Bid Documents in response to / to address the request / clarification of the prospective bidder/s who attended the pre-bid conference held on 19 January 2024:

1. *The following should be modified the Invitation to Bid (Section I) as:*

No.	From	To
<b>8</b>	Bids must be duly received by the UP-PGH BAC 1 Secretariat through manual submission at the office address indicated below, on or before 9:00AM, 02 February 2024. Late bids shall not be accepted.	Bids must be duly received by the UP-PGH BAC 1 Secretariat through manual submission at the office address indicated below, on or before <b><u>9:00AM, 16 February 2024</u></b> . Late bids shall not be accepted.
<b>10</b>	Bid opening shall be on 9:30 AM, 02 February 2024, at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.	Bid opening shall be on <b><u>9:30 AM, 16 February 2024</u></b> at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.

2. *The following should be modified the Special Conditions of Contract (Section V) as:*

GCC Clause	From	To
<b>1</b>	<p>Delivery and Documents –</p> <p>For purposes of the Contract, “EXW,” “FOB,” “FCA,” “CIF,” “CIP,” “DDP” and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:</p>	<p>Delivery and Documents –</p> <p>For purposes of the Contract, “EXW,” “FOB,” “FCA,” “CIF,” “CIP,” “DDP” and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:</p>

<b>GCC Clause</b>	<b>From</b>	<b>To</b>
	<p>[For Goods supplied from abroad, state:] “The delivery terms applicable to the Contract are DDP delivered [indicate place of destination]. In accordance with INCOTERMS.”</p> <p>“The delivery terms applicable to this Contract are delivered to the University of the Philippines Manila – Philippine General Hospital. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination.”</p> <p>Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI (Schedule of Requirements).</p> <p>For purposes of this Clause the Procuring Entity’s Representative at the Project Site is Maria Bernadette P. Idjao, MMPA, Chief Administrative Officer – Property and Supply Division and Emelita O. Lavilla, RND, MHA, Chief, Dietary Department.</p>	<p>[For Goods supplied from abroad, state:] “The delivery terms applicable to the Contract are DDP delivered [indicate place of destination]. In accordance with INCOTERMS.”</p> <p>“The delivery terms applicable to this Contract are delivered to the University of the Philippines Manila – Philippine General Hospital. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination.”</p> <p>Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI (Schedule of Requirements).</p> <p>For purposes of this Clause the Procuring Entity’s Representative at the Project Site is Maria Bernadette P. Idjao, MMPA, Chief Administrative Officer – Property and Supply Division <del>and Emelita O. Lavilla, RND, MHA, Chief, Dietary Department.</del></p>

3. *Clarification on the Terms and Conditions:*

<b>Query</b>	<b>Remarks / Response</b>
If we can submit Certificate of No Adverse Drug reaction in lieu of Certificate of Acceptance (for new brand offer).	As discussed during the pre-bid conference, Certificate of No Adverse Reaction maybe considered in place of Certificate of Acceptance for new brand offer.
<p>The brand offered must be at least five (5) years commercially available in the market from date of opening of bids. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).</p> <p>Certificate of Acceptance from at least three (3) major hospitals.</p>	<p>The agency’s requirement for the brand offered must be at least five (5) years commercially available in the market and the submission of Certificate of Acceptance from at least three (3) major hospitals shall remain to ensure that the offered drugs and medicines are already being used in major hospitals and not subject for any product recall or product complaint. Also, as a requirement set by the hospital’s Pharmacy and Therapeutics Committee, a 5-year existence of a drug in the market will minimize risks and prioritize patient safety. This ensures that patients are not given drugs that have not undergone sufficient testing to establish safety and efficacy.</p> <p>Established track record: A drug that has been in the market for a longer period has an established track record of use. This allows for better understanding of potential side effects and complications, and can lead to better management of these issues, as opposed to the unknown risks that new drugs may pose.</p>

Query	Remarks / Response
	<p>Better pharmacovigilance: A drug that has been in the market for a longer period has gone through post-marketing surveillance, which allows for the identification and management of potential safety issues. By requiring a longer period of existence in the market, the drug regulatory body can be confident in the level of systems in place for pharmacovigilance.</p> <p>Having a product registered through the FDA may mean that it has passed preliminary safety tests for a certain population before product use BUT SAFETY AFTER product registration or post marketing surveillance is above and beyond all other considerations.</p>
Memorandum of Agreement (MOA) and Certificate of Exclusive / Authorized Distributorship	The title / heading of the required "MOA" may vary depending on the agreement executed by the manufacturer and exclusive / authorized distributor. However, the purpose of having the authority to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distribution agreement. Compliance with the submission of the MOA and Certificate of Exclusive / Authorized Distributorship between the manufacturer and distributor is required.
<p>Renewal of Certificate of Product Registration (CPR) – Official Receipt</p> <p>With respect to the above three (3) months requirement, may we respectfully seek clarification for the legal basis thereof since the CPRs are on its face valid, unless revoked or not renewed.</p>	As stated in the FDA Circular No. 2011-004, the FDA considers the renewal of CPR's as valid and existing provided it is filed within the 120-day period (4 months) from its date of expiry. Compliance of the company is required to submit proof of payment and filing. The hospital is still lenient in its requirements of three (3) months.
Will you accept expired Certificate of Analysis (COA) with proof of on-going application to local laboratories?	A product's certificate of analysis provides the end-user proof that the drug offered contains the appropriate amount of Active Pharmaceutical Ingredient (API) as specified in its formulation. Without a valid COA, we cannot ensure the quality or potency or concentration of the API in the product. An expired COA is, therefore, <b>unacceptable</b> .
Single Largest Completed Contract (SLCC)	<p>As stated in Section II – Instructions to Bidders Item 5.3.b, "For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC"</p> <p>Statement of the Single Largest Completed Contract must be supported with:</p> <ol style="list-style-type: none"> <li>1. Contract</li> <li>2. Certificate of Completion</li> <li>3. Certificate of Acceptance</li> </ol>

Query	Remarks / Response
	All submitted documents will be subject to verification and validation during the post-qualification.
Notarized Questionnaire for Prospective Bidders	Required submission of UP Questionnaire for Prospective Bidders should be notarized
Joint Venture Agreement	Please refer to Section 23 of the 2016 IRR of RA 9184 – Eligibility Requirements for the Procurement of Goods and Infrastructure Projects
The prospective bidders are requesting to exclude the required attachment as part of the Statement of All On-Going Government and Private Contracts  1. Notice of Award and/or Contract 2. Notice to Proceed	Request granted.  The Statement of All On-going Government and Private Contracts (including Contracts Awarded but not yet started) for the last two (2) years shall be provided.  However, during the post-qualification documentations may be required if needed.

4. Clarification on the following line items:

Item No.	From	To
<b>3</b>	Albumin Human 20%, 50mL bottle (IV, IV infusion)  <i>Offer: Albumin Human 20%, 50mL vial (IV, IV infusion)</i>	Vial or bottle will be considered
<b>63</b>	Epoetin alfa (recombinant human erythropoietin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)  <i>Offer: Epoetin alfa (recombinant human erythropoietin) 4000 IU/mL, 1mL, pre-filled syringe (IV, SC)</i>	The specifications were based from the end-users and their historical consumption.
<b>71</b>	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)  <i>Offer: Filgrastim 300 micrograms/0.9 mL, vial (IV, SC)</i>	The specifications were based from the end-users and their historical consumption.
<b>83</b>	Glucose (dextrose) 50%, 50mL vial (IV)  <i>Offer: Glucose (dextrose) 50%, 50mL, ampule (IV)</i>	The vial formulation is preferred than the ampule for use by multiple patients.
<b>88</b>	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)  <i>Offer: Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (Ovine origin)</i>	As stated in the formulary, the drug must be of Bovine origin.
<b>89</b>	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	As stated in the formulary, the drug must be of Bovine origin.

Item No.	From	To
	<i>Offer: Heparin sodium unfractionated 5,000 iu/mL, 5mL vial (IV infusion, SC) (Ovine origin)</i>	
<b>107</b>	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial  <i>Offer: Levofloxacin 5mg/mL solution for IV infusion, 100mL bottle</i>	Levofloxacin: Solution for IV infusion will be considered
<b>123</b>	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)  <i>Offer: Metronidazole 5mg/mL, 100mL bottle (IV infusion)</i>	Vial or bottle will be considered.
<b>124</b>	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)  <i>Offer: Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL vial (IM, IV) with PDEA Permit)</i>	As stated in the PNF: for 5mg/5ml, ampule or vial maybe used, but for 5mg/1ml, packaging should be in ampules.
<b>141</b>	Oxaliplatin 50mg vial powder (IV Infusion)  <i>Offer: Oxaliplatin 5mg/mL concentrate solution, 10mL vial infusion</i>	The use of the concentrated solution with the same total concentration per vial (50mg) may be used.
<b>156</b>	Potassium chloride 2meq/mL, 20mL vial (IV infusion)  <i>Offer: Potassium Chloride 2meq/ml, 20ml ampule (IV infusion)</i>	The vial formulation is preferred that the ampule for use by multiple patients.

This shall form an integral part of the Bid Documents.

For the information and guidance of all concerned.

**Dean CHARLOTTE M. CHIONG, MD, PhD**  
*Chairperson, Bids and Awards Committee 1*

Received by the Bidder:

\_\_\_\_\_  
*Signature over Printed Name*

\_\_\_\_\_  
*Name of Company*

\_\_\_\_\_  
*Date*